International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease by Williamson, K, Lytvyak, E, De Krijger, M, Trivedi, P, Estes, D, Yu, L, Pratt, D, De Vries, A, Daretti, L, Liu, C, Bowlus, C, Marschall, H, Montano-Loza, A, Chapman, R, Van Der Woude, C, Marzioni, M, Keshav, S, Ponsioen, C, Hirschfield, G, Levy, C

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases by Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C